Proteoglycan binding as proatherogenic function metric of apoB-containing lipoproteins and chronic kidney graft failure

Hannah L. M. Steffen, Josephine L. C. Anderson, Margot L. Poot, Yu Lei, Margery A. Connelly, Stephan J. L. Bakker, Katariina Oorni, Uwe J. F. Tietge*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Lipoprotein-proteoglycan binding is an early key event in atherosclerotic lesion formation and thus conceivably could play a major role in vasculopathy-driven chronic graft failure and cardiovascular mortality in renal transplant recipients. The present study investigated whether lipoproteinproteoglycan binding susceptibility (LPBS) of apoBcontaining lipoproteins and levels of the classical atherosclerosis biomarker LDL-C were associated with cardiovascular mortality (n = 130) and graft failure (n = 73) in 589 renal transplant recipients who were followed up from at least 1 year after transplantation for 9.5 years. At baseline, LPBS was significantly higher in patients who subsequently developed graft failure than in those with a surviving graft (1.68 +/- 0.93 vs. 1.46 +/- 0.49 nmol/mmol, P = 0.001). Cox regression analysis showed an association between LPBS and chronic graft failure in an age-and sex-adjusted model (hazard ratio: 1.45; 95% CI, 1.14-1.85; P = 0.002), but no association was observed with cardiovascular mortality. LDL-C levels were not associated with graft failure or cardiovascular mortality. This study shows that measurement of cholesterol retention outperformed the traditionally used quantitative parameter of LDL-C levels in predicting graft failure, suggesting a higher relevance of proatherogenic function than the quantity of apoBcontaining lipoproteins in chronic kidney graft failure.

Original languageEnglish
Article number100083
Number of pages9
JournalJournal of Lipid Research
Volume62
Early online date30-Apr-2021
DOIs
Publication statusPublished - 2021

Keywords

  • chronic graft failure
  • transplant vasculopathy
  • proteoglycans
  • cholesterol
  • atherosclerosis
  • LDL
  • prospective
  • lipoprotein-proteoglycan binding susceptibility
  • cardiovascular mortality
  • kidney transplantation
  • LOW-DENSITY LIPOPROTEINS
  • HUMAN AORTIC PROTEOGLYCANS
  • MUSCLE-CELL PROTEOGLYCANS
  • CHOLESTEROL
  • PARTICLES
  • AFFINITY
  • ATHEROSCLEROSIS
  • COMPLICATIONS
  • AGGREGATION

Cite this